Literature DB >> 6750429

Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis.

M E Smith, L A Amaducci.   

Abstract

Inhibitors of proteolytic enzymes were tested for their ability to suppress the clinical signs and CNS lesions produced by injection of purified myelin in complete Freund's adjuvant into Lewis rats. Pepstatin or a series of neutral protease inhibitors including aprotinin, soybean trypsin inhibitor, leupeptin, antipain, trans-aminomethyl cyclohexane carboxylic acid (AMCA), epsilon-amino caproic acid (EACA) nitrophenyl guanidino benzoate (NPGB), D- and L-polylysine, or a new commercial protease inhibitor, dipropionyl Rhein (DPR) were injected daily beginning on day 7 after immunization of rats with myelin. Aprotinin and soybean trypsin inhibitor exacerbated the symptoms and lesions of experimental allergic encephalomyelitis (EAE), leupeptin and antipain had no effect, and the plasminogen activators AMCA, EACA, NPGB, as well as poly-L- and poly-D-lysine and DPR suppressed various aspects of EAE. The measurement of acid protease as a biochemical method for quantitation of the degree of cellular infiltration into the CNS is proposed, and the results with the various treatments presented. AMCA and NPGB may exert their effects at the site of entrance of the lymphoid cells into the CNS.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6750429     DOI: 10.1007/bf00965121

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

1.  Suppression of experimental allergic encephalomyelitis in guinea-pigs with poly-L-lysine.

Authors:  E Chelmicka-Szorc; B G Arnason
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

2.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

3.  Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis.

Authors:  C F Brosnan; W Cammer; W T Norton; B R Bloom
Journal:  Nature       Date:  1980-05-22       Impact factor: 49.962

4.  Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin).

Authors:  D H Boehme; H Umezawa; G Hashim; N Marks
Journal:  Neurochem Res       Date:  1978-04       Impact factor: 3.996

5.  A thiol proteinase highly elevated in and around the plaques of multiple sclerosis. Some biochemical parameters of plaque activity and progression.

Authors:  H E Hirsch; M E Parks
Journal:  J Neurochem       Date:  1979-02       Impact factor: 5.372

6.  Proteinases and demyelination.

Authors:  H E Hirsch
Journal:  J Histochem Cytochem       Date:  1981-03       Impact factor: 2.479

7.  Proteolytic enzymes and experimental demyelination in the rat and monkey.

Authors:  M E Smith; L M Sedgewick; J S Tagg
Journal:  J Neurochem       Date:  1974-11       Impact factor: 5.372

8.  Neutral protease activity in lymphocytes of Lewis rats with acute experimental allergic encephalomyelitis.

Authors:  M E Smith
Journal:  Neurochem Res       Date:  1979-12       Impact factor: 3.996

9.  Inhibition of intracellular protein degradation by pepstatinyl, poly(L-lysine), and pepstatinyl-poly(L-lysine).

Authors:  P Campbell; G I Glover; J M Gunn
Journal:  Arch Biochem Biophys       Date:  1980-09       Impact factor: 4.013

10.  Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination.

Authors:  W Cammer; B R Bloom; W T Norton; S Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

View more
  9 in total

Review 1.  Proteinases in inflammatory demyelinating disease.

Authors:  C T Bever; J N Whitaker
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Lysosomal enzymes in experimental allergic encephalomyelitis: time course and evidence of the source.

Authors:  L Massacesi; A L Abbamondi; L Raimondi; C Giorgi; L Amaducci
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

3.  Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.

Authors:  Maureen A Shaw; Zhen Gao; Kathryn E McElhinney; Sherry Thornton; Matthew J Flick; Adam Lane; Jay L Degen; Jae Kyu Ryu; Katerina Akassoglou; Eric S Mullins
Journal:  J Neurosci       Date:  2017-03-08       Impact factor: 6.167

4.  NPGB-induced inhibition of superoxide anion production by normal Lewis rat macrophages.

Authors:  A Arduini; G Mancinelli; M Belfiglio; J DeJulia; V Damonti; S Storto; G Federici
Journal:  Neurochem Res       Date:  1989-01       Impact factor: 3.996

5.  Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790.

Authors:  A K Hewson; T Smith; J P Leonard; M L Cuzner
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

6.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.

Authors:  K Gijbels; R E Galardy; L Steinman
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

7.  Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE).

Authors:  T Inuzuka; S Sato; H Baba; T Miyatake
Journal:  Neurochem Res       Date:  1988-03       Impact factor: 3.996

8.  Proteolytic activity in brains of rabbits treated with aluminum.

Authors:  M Benuck; K Iqbal; H M Wisniewski; A Lajtha
Journal:  Neurochem Res       Date:  1985-06       Impact factor: 3.996

Review 9.  Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases.

Authors:  Marjana Brkic; Sriram Balusu; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.